Edit |   |
---|---|
Antigenic Specificity | PDCD1/PD1/CD279 (Cemiplimab biosimilar) |
Clone | monoclonal |
Host Species | Recombinant Human |
Reactive Species | human |
Isotype | IgG4 kappa |
Format | Protein A/G purified |
Size | 100 µg, 1 mg, |
Concentration | typically between 0.5-2.0 mg/ml. |
Applications | ELISA, WB |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | Cemiplimab is a monoclonal antibody biosimilar expressed in CHO cells, targeting PDCD1/PD1/CD279, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Cemiplimab is a fully human PD-1 antibody. The first indication for the marketing application is metastatic/locally advanced cutaneous squamous cell carcinoma (Cutaneous Squamous Cell Carcinoma, CSCC). It is an intravenous immunotherapy targeting the PD-1 pathway, which can help the immune system fight cancer cells. |
Immunogen | n/a |
Other Names | Cemiplimab, PDCD1/PD1/CD279, 1801342-60-8 |
Gene, Accession # | CAS: 1801342-60-8 |
Catalog # | abx831484 |
Price | please inquire |
Order / More Info | PDCD1/PD1/CD279 (Cemiplimab biosimilar) Antibody from ABBEXA LTD |
Product Specific References | n/a |
U.S. Office
118 Eldridge Rd, Suite C,
Sugar Land, TX 77478 USA
Telephone: +1 832 327 7413
Netherlands Office
Abbexa BV
Wattstraat 54 2723 RD,
Zoetermeer,Netherlands
Telephone: +44 (0) 1223 755950